Man Group plc Acquires Shares of 26,770 Beta Bionics, Inc. $BBNX

Man Group plc purchased a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 26,770 shares of the company’s stock, valued at approximately $419,000. Man Group plc owned about 0.06% of Beta Bionics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in Beta Bionics in the first quarter valued at about $29,000. Summit Securities Group LLC acquired a new position in Beta Bionics during the fourth quarter valued at approximately $52,000. Legal & General Group Plc grew its holdings in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Beta Bionics in the first quarter valued at approximately $95,000.

Beta Bionics Stock Down 2.5%

Shares of NASDAQ:BBNX opened at $19.42 on Friday. The firm has a market cap of $873.71 million, a price-to-earnings ratio of -11.77 and a beta of 3.37. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The company’s fifty day simple moving average is $17.17 and its 200 day simple moving average is $13.65.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Research analysts expect that Beta Bionics, Inc. will post -2.1 earnings per share for the current fiscal year.

Insider Transactions at Beta Bionics

In other news, insider Mark Hopman sold 5,327 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97. Following the completion of the transaction, the insider directly owned 124,027 shares of the company’s stock, valued at $2,370,155.97. This represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the transaction, the insider owned 169,628 shares of the company’s stock, valued at approximately $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 33,262 shares of company stock valued at $604,002. 5.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BBNX shares. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Bank of America reduced their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Truist Financial boosted their target price on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. The Goldman Sachs Group increased their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, William Blair started coverage on Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating on the stock. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Beta Bionics Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.